KalVista Pharmaceuticals (KALV) Misses Q1 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($1.12), $0.16 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $951.67 thousand.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Subaru, other Japan suppliers to team on delivery as Boeing raises output - Nikkei
• KKR sells Nordic Bioscience stake back to founder
• Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance